EP0959885A4 - Triaryl substituierte imidazole und verfahren zur verwendung - Google Patents

Triaryl substituierte imidazole und verfahren zur verwendung

Info

Publication number
EP0959885A4
EP0959885A4 EP97948327A EP97948327A EP0959885A4 EP 0959885 A4 EP0959885 A4 EP 0959885A4 EP 97948327 A EP97948327 A EP 97948327A EP 97948327 A EP97948327 A EP 97948327A EP 0959885 A4 EP0959885 A4 EP 0959885A4
Authority
EP
European Patent Office
Prior art keywords
methods
substituted imidazoles
triaryl substituted
triaryl
imidazoles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97948327A
Other languages
English (en)
French (fr)
Other versions
EP0959885A1 (de
Inventor
Linda L Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9700559.9A external-priority patent/GB9700559D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0959885A1 publication Critical patent/EP0959885A1/de
Publication of EP0959885A4 publication Critical patent/EP0959885A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP97948327A 1996-11-20 1997-11-17 Triaryl substituierte imidazole und verfahren zur verwendung Withdrawn EP0959885A4 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3146896P 1996-11-20 1996-11-20
US31468P 1996-11-20
GB9700559 1997-01-13
GBGB9700559.9A GB9700559D0 (en) 1997-01-13 1997-01-13 Triaryl substituted imidazoles and methods of use
PCT/US1997/020955 WO1998022108A1 (en) 1996-11-20 1997-11-17 Triaryl substituted imidazoles and methods of use

Publications (2)

Publication Number Publication Date
EP0959885A1 EP0959885A1 (de) 1999-12-01
EP0959885A4 true EP0959885A4 (de) 2002-07-17

Family

ID=26310784

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97948327A Withdrawn EP0959885A4 (de) 1996-11-20 1997-11-17 Triaryl substituierte imidazole und verfahren zur verwendung

Country Status (5)

Country Link
EP (1) EP0959885A4 (de)
JP (1) JP2001504489A (de)
AU (1) AU726311B2 (de)
CA (1) CA2271941A1 (de)
WO (1) WO1998022108A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503949B1 (en) 1999-05-17 2003-01-07 Noro Nordisk A/S Glucagon antagonists/inverse agonists
EP1741445B1 (de) 2000-01-21 2013-08-14 Novartis AG Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
US6821960B2 (en) 2000-11-17 2004-11-23 Noyo Nordisk Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
US6706744B2 (en) 2000-11-17 2004-03-16 Novo Nordisk A/S Glucagon antagonists/inverse agonists
EP1345890A1 (de) 2000-11-17 2003-09-24 Novo Nordisk A/S Glucagon-antagonisten/inverse agonisten
WO2003024447A1 (en) * 2001-09-20 2003-03-27 Smithkline Beecham Corporation Inhibitors of glycogen synthase kinase-3
ES2256560T3 (es) * 2001-10-12 2006-07-16 Bayer Pharmaceuticals Corporation Heterociclos de 5 mienbros que contienen nitrogeno sustituidos con felino para el tratamiento de la obesidad.
US6881746B2 (en) 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
US6762318B2 (en) 2001-12-03 2004-07-13 Novo Nordisk A/S Glucagon antagonists
AU2003299791A1 (en) * 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
DE602004030318D1 (de) 2003-01-27 2011-01-13 Merck Sharp & Dohme Substituierte pyrazole, zusammensetzungen,die solche verbindungen enthalten, und anwendungsverfahren
US7301036B2 (en) 2003-12-19 2007-11-27 Merck & Co., Inc. Cyclic guanidines, compositions containing such compounds and methods of use
ATE395338T1 (de) 2004-06-04 2008-05-15 Merck & Co Inc Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren
JP2008505905A (ja) 2004-07-07 2008-02-28 メルク　エンド　カムパニー　インコーポレーテッド ピラゾールアミド誘導体、こうした化合物を含有する組成物および使用方法
EP1773330B1 (de) 2004-07-22 2010-05-26 Merck Sharp & Dohme Corp. Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung
JP2008533200A (ja) 2005-03-21 2008-08-21 メルク エンド カムパニー インコーポレーテッド 置換アリールおよびヘテロアリール誘導体、かかる化合物を含有する組成物および使用法
WO2006104826A2 (en) 2005-03-30 2006-10-05 Merck & Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
AU2006276072A1 (en) 2005-07-26 2007-02-08 Merck Sharp & Dohme Corp. Process for synthesizing a substituted pyrazole
CA2622608C (en) 2005-09-14 2014-08-19 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
EP2001472A2 (de) 2006-03-23 2008-12-17 Merck and Co., Inc. Glucagon-rezeptor-antagonisten-verbindungen, zusammensetzungen mit solchen verbindungen und verfahren zu ihrer verwendung
JP2009537525A (ja) 2006-05-16 2009-10-29 メルク エンド カムパニー インコーポレーテッド グルカゴン受容体アンタゴニスト化合物、このような化合物を含む組成物及び使用方法
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
SI2531501T1 (sl) 2010-02-03 2014-04-30 Takeda Pharmaceutical Company Limited Inhibitorji kinaze-1, ki regulirajo signal apoptoze
US9649294B2 (en) 2013-11-04 2017-05-16 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
ES2926931T3 (es) * 2014-02-07 2022-10-31 Agency Science Tech & Res Inhibidores de caseína quinasa 1 basados en azoles 2,4,5-tri-sustituidos como inductores de la cardiomiogénesis
US20180044316A1 (en) * 2015-03-05 2018-02-15 University Of Notre Dame Du Lac Potentiators of beta-lactam antibiotics
US11958828B1 (en) 2023-11-07 2024-04-16 King Faisal University 4,5-bis(4-bromophenyl)-1-hexyl-2-(3-pyridyl)-1H-imidazole as an antimicrobial compound
US12180169B1 (en) 2023-12-28 2024-12-31 King Faisal University 4-[4,4-bis(4-bromophenyl)-5-oxo-2-thioxoimidazolidin-1-yl]butanoic acid as an antimicrobial compound
US11993575B1 (en) 2023-12-29 2024-05-28 King Faisal University Ethyl [4,4-bis(4-bromophenyl)-2,5-dioxoimidazolidin-1-yl]acetate as an antimicrobial compound
US12180168B1 (en) 2024-01-02 2024-12-31 King Faisal University 3-[4,4-bis(4-nitrophenyl)-2,5-dioxoimidazolidin-1-yl]propanoic acid as an antimicrobial compound
US12180167B1 (en) 2024-01-02 2024-12-31 King Faisal University 6-[4,4-bis(4-bromophenyl)-2,5-dioxoimidazolidin-1-yl]hexanoic acid as an antimicrobial compound
US11970462B1 (en) 2024-01-03 2024-04-30 King Faisal University Ethyl 3-[4,4-bis(4-chlorophenyl)-2,5-dioxoimidazolidin-1-yl]propanoate as an antimicrobial compound

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929807A (en) * 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US4430326A (en) * 1981-12-22 1984-02-07 University Patents, Inc. Method of diminishing glucose levels resulting from endogenous glucagon
WO1993014081A1 (en) * 1992-01-13 1993-07-22 Smithkline Beecham Corporation Imidazole derivatives and their use as cytokine inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3707475A (en) * 1970-11-16 1972-12-26 Pfizer Antiinflammatory imidazoles
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3929807A (en) * 1971-05-10 1975-12-30 Ciba Geigy Corp 2-Substituted-4(5)-(aryl)-5(4)-(2,3 or -4-pyridyl)-imidazoles
US4430326A (en) * 1981-12-22 1984-02-07 University Patents, Inc. Method of diminishing glucose levels resulting from endogenous glucagon
WO1993014081A1 (en) * 1992-01-13 1993-07-22 Smithkline Beecham Corporation Imidazole derivatives and their use as cytokine inhibitors

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANESTEZIOLOGIIA I REANIMATOLOGIIA. RUSSIA 1996 SEP-OCT, no. 5, September 1996 (1996-09-01), pages 29 - 39, ISSN: 0201-7563 *
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS. UNITED STATES 1 FEB 1993, vol. 300, no. 2, 1 February 1993 (1993-02-01), pages 747 - 750, ISSN: 0003-9861 *
DATABASE MEDLINE [online] 1 February 1993 (1993-02-01), UNSON C G ET AL: "The role of histidine-1 in glucagon action.", XP002199270, Database accession no. NLM8382034 *
DATABASE MEDLINE [online] 1996, DEL REY A ET AL: "Metabolic and endocrine effects of interleukin-1 in obese, diabetic Zucker fa/fa rats.", XP002199269, Database accession no. NLM8886749 *
DATABASE MEDLINE [online] September 1996 (1996-09-01), MAYER N A ET AL: "The utilization of nutrient substances during wound healing", XP002199268, Database accession no. NLM9027251 *
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES: OFFICIAL JOURNAL, GERMAN SOCIETY OF ENDOCRINOLOGY [AND] GERMAN DIABETES ASSOCIATION. GERMANY 1996, vol. 104, no. 4, 1996, pages 317 - 326, ISSN: 0947-7349 *
See also references of WO9822108A1 *

Also Published As

Publication number Publication date
AU726311B2 (en) 2000-11-02
JP2001504489A (ja) 2001-04-03
CA2271941A1 (en) 1998-05-28
EP0959885A1 (de) 1999-12-01
AU5441498A (en) 1998-06-10
WO1998022108A1 (en) 1998-05-28

Similar Documents

Publication Publication Date Title
EP0959885A4 (de) Triaryl substituierte imidazole und verfahren zur verwendung
EP1047347A4 (de) Geriffelte elektroden und methoden zu ihrer anwendung
EP1027066A4 (de) Lösliche mhc komplexe und methoden zu deren verwendung
EP0789553A4 (de) Desodorierende, antimikrobielle und konservierende mittel und ihre verwendungen
NO995247D0 (no) Benyttelse av utstyr i et brönnsystem
EP0880356A4 (de) Antimikrobielle peptide und anwendungsverfahren
EP0856155A4 (de) Fluoreszent- und lumineszentmarkierungszusammensetzungen und verfahren zu ihrer verwendung
EP0918534A4 (de) Medikamentenvorstufen auf peptidbasis und verfahren zur ihrer herstellung und nutzung
EP0948257A4 (de) Triaryl-substituierte imidazole, sie enthaltende zusammensetzungen und verfahren zu ihrer verwendung
EP1037911A4 (de) Anti-pathogen system und verfahren zu dessen benutzung
DE69622971D1 (de) Variabler "Linear-in-Dezibel" Verstärker
DE69522528D1 (de) Kathetereinfuehrsystem
DE69531544D1 (de) Kathetersystem
DE69535919D1 (de) Kathetersystem
EP0910301A4 (de) Zusammensetzungen und verfahren zum bekleiden von medizinischen vorrichtungen
IT1273546B (it) Apparecchiatura radiodiagnostica
ID18623A (id) Turunan-turunan naftiridin
DE69503688D1 (de) Kabelbinder
EP0796079A4 (de) Feste silikonzusammensetzungen und verfahren zur herstellung und verwendung
EP1076565A4 (de) Indolicin-analoga und methoden zu deren verwendung
EP1056457A4 (de) S-lanzoprazol zusammensetzungen und -verfahren
EP1240201A4 (de) Oxidierte apolipoproteine und verfahren zu deren anwendung
EP0888267A4 (de) Neue pyruvatverbindungen und verfahren zu ihrer anwendung
EP1147126A4 (de) Co-faktoren für trophische faktoren und methoden für deren verwendung
FR2754739B1 (fr) Compositions anti-mousse et compositions anhydres intermediaires

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990621

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020604

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 9/12 B

Ipc: 7A 61P 3/10 B

Ipc: 7A 61P 3/04 B

Ipc: 7A 61K 31/44 A

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030904